Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial.

"Conflict of Interest Statement Dr. Daneng Li reports research funding to his institution from AstraZeneca and Brooklyn ImmunoTherapeutics. He serves as a consultant and has received honoraria from Adagene, Advanced Accelerator Applications, Bayer Healthcare, Coherus BioSciences, Eisai, Exelixis, Genentech, Ipsen Biopharmaceuticals, Lexicon Pharmaceuticals, Merck, MiNA Therapeutics, QED Therapeutics, Servier, Sun Pharma, Taiho Pharmaceutical, and TerSera Therapeutics. Dr. Han Chong Toh has received research funding from Bristol Myers Squibb, Merck, and Bayer Healthcare; honoraria from Roche, Merck, and Eisai; and consultancy fee from Tessa Therapeutics Ltd. Dr. Philippe Merle has received advisory board fees from Bayer Healthcare, Bristol Myers Squibb, Eisai, Eli Lilly and Company, Ipsen Biopharmaceuticals, Merck, and Roche. Dr. Kaoru Tsuchiya has received lecture fees from Eisai, Chugai Pharmaceutical, and Eli Lilly. Dr. Sairy Hernandez is employed by Genentech USA. Dr. Wendy Verret was employed by Genentech USA at the time the analysis was completed. Dr. Alan Nicholas is employed by Genentech USA. Dr. Masatoshi Kudo has received grant support from AbbVie, Dainippon Sumitomo Pharma, Gilead Sciences, Otsuka Pharmaceutical, Taiho Pharmaceutical, and Takeda Medical Research Foundation; grant support and consulting fees from Bayer and Merck; grant support, lecture fees, and consulting fees from Bristol Myers Squibb and Eisai; consulting fees from Chugai Pharmaceutical and Ono Pharmaceutical; and is the Editor-in-Chief of Liver Cancer. No other potential conflict of interest relevant to this article was reported."

"This study was funded by F. Hoffmann-La Roche/Genentech. The study was designed and data analyzed by the sponsor in collaboration with the investigators. Editorial support was provided by Thea Gray of Health Interactions and funded by the sponsor."